We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
The decision of the U.S. Supreme Court in Association for Molecular Pathology v. Myriad Genetics, Inc.1 was a landmark case addressing the subject matter provisions in Section 101 of the United States’ Patent Act.2 Represented by public-interest litigators from the American Civil Liberties Union (ACLU) and the Public Patent Foundation, a coalition of scientists, cancer patients, and genetic counselors successfully challenged and invalidated patents covering genetic DNA sequences. The Supreme Court decision drastically revised the understanding of patent-eligible subject matter, with sweeping implications for women’s health, for medical research, and for commercial biotechnology.
The chapters in this volume on pharmaceutical development and on the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPRGFA) are oriented toward the use of liability rules to promote innovation. Each describes an attempt to re-align the incentives of innovators by structuring a set of contractual options that will overcome the barriers to investment. In response to the formidable barriers to development of viable pharmaceuticals from private libraries of receptors and ligands, Rai et al. propose the creation of a private molecular “semi-commons” of pooled molecules from which promising drug targets could be tested, and for which a contributor would be paid if a viable product resulted. In a similar vein, Henson-Apollonio reports on the structure of the ITPRGFA, which allows use of genetic resources with the guarantee of a royalty if a contributor's variety is used.
A common feature of these systems is a type of conscription mechanism that permits a participant in the system to use intellectual property (IP) without a direct negotiation with the IP owner. Users of an asset are required to pay for their use of the asset; they cannot be refused use of that asset but they control the decision whether to take the asset or not. In other words, owners of the asset have a right to payment, but not a right to exclude.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.